Repeated cannabinoid administration increases indices of noradrenergic activity in rats

Pharmacology Biochemistry and Behavior

Volumn 86, Issue 1, 2007, Pages 162-168

  Page, M E ^a   Oropeza, V C ^a   Sparks, S E ^a   Qian, Y ^a   Menko, A S ^a   Van Bockstaele, E J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

CB1 receptor; Elevated plus maze; Microdialysis; Norepinephrine; Tyrosine hydroxylase; Western blot; WIN 55,212 2

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID; CANNABINOID RECEPTOR AGONIST; TYROSINE 3 MONOOXYGENASE;

ADRENERGIC ACTIVITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; BRAIN CORTEX; CANNABIS ADDICTION; CATECHOLAMINE RELEASE; CONTROLLED STUDY; DOSE RESPONSE; ENZYME SYNTHESIS; LOCUS CERULEUS; MAZE TEST; NONHUMAN; NORADRENALIN RELEASE; NORADRENERGIC ACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REPEATED DRUG DOSE;

ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; BENZOXAZINES; BLOTTING, WESTERN; CANNABINOIDS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; EXTRACELLULAR SPACE; MALE; MICRODIALYSIS; MORPHOLINES; NAPHTHALENES; NOREPINEPHRINE; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; STIMULATION, CHEMICAL; TYROSINE 3-MONOOXYGENASE;

ANIMALIA; RATTUS;

EID: 33847078481     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2006.12.020     Document Type: Article

References (51)

1. Aceto M.D., Scates S.M., and Martin B.B. Spontaneous and precipitated withdrawal with a synthetic cannabinoid, WIN 55212-2. Eur J Pharmacol 416 (2001) 75-81
2. Arendt M., and Munk-Jorgensen P. Heavy cannabis users seeking treatment - prevalence of psychiatric disorders. Soc Psychiatry Psychiatr Epidemiol 39 (2004) 97-105
3. Arnold J.C., Topple A.N., Mallet P.E., Hunt G.E., and McGregor I.S. The distribution of cannabinoid-induced Fos expression in rat brain: differences between the Lewis and Wistar strain. Brain Res 921 (2001) 240-255
4. Aston-Jones G., and Bloom F.E. Norepinephrine-containing locus coeruleus neurons in behaving rats exhibit pronounced responses to non-noxious environmental stimuli. J Neurosci 1 (1981) 887-900
5. Aston-Jones G., Foote S.L., and Bloom F.E. Anatomy and physiology of locus coeruleus neurons: functional implications. In: Ziegler M., and Lake C.R. (Eds). Norepinephrine (frontiers of clinical neuroscience) (1984), Williams and Wilkins, Baltimore 92-116
6. Aston-Jones G., Chiang C., and Alexinsky T. Discharge of noradrenergic locus coeruleus neurons in behaving rats and monkeys suggests a role in vigilance. Prog Brain Res 88 (1991) 501-520
7. Aston-Jones G., Rajkowski J., and Cohen J. Role of locus coeruleus in attention and behavioral flexibility. Biol Psychiatry 46 (1999) 1309-1320
8. Berrendero F., and Maldonado R. Involvement of the opioid system in the anxiolytic-like effects induced by Delta(9)-tetrahydrocannabinol. Psychopharmacology 163 (2002) 111-117
9. Bonnin A., de Miguel R., Fernandez-Ruiz J.J., Cebeira M., and Ramos J.A. Possible role of the cytochrome P450-linked monooxygenase system in preventing delta 9-tetrahydrocannabinol-induced stimulation of tuberoinfundibular dopaminergic activity in female rats. Biochem Pharmacol 48 (1994) 1387-1392
10. Bonnin A., de Miguel R., Hernandez M.L., Ramos J.A., and Fernandez-Ruiz J.J. The prenatal exposure to delta 9-tetrahydrocannabinol affects the gene expression and the activity of tyrosine hydroxylase during early brain development. Life Sci 56 (1995) 2177-2184
11. Bonnin A., de Miguel R., Castro J.G., Ramos J.A., and Fernandez-Ruiz J.J. Effects of perinatal exposure to delta 9-tetrahydrocannabinol on the fetal and early postnatal development of tyrosine hydroxylase-containing neurons in rat brain. J Mol Neurosci 7 (1996) 291-308
12. Boundy V.A., Gold S.J., Messer C.J., Chen J., Son J.H., Joh T.H., et al. Regulation of tyrosine hydroxylase promoter activity by chronic morphine in TH9.0-LacZ transgenic mice. J Neurosci 18 (1998) 9989-9995
13. Dackis C.A., and O'Brien C.P. Cocaine dependence: a disease of the brain's reward centers. J Subst Abuse Treat 21 (2001) 111-117
14. Dawson G.R., and Tricklebank M.D. Use of the elevated plus maze in the search for novel anxiolytic agents. Trends Pharmacol Sci 16 (1995) 33-36
15. Degenhardt L., Hall W., and Lynskey M. The relationship between cannabis use, depression and anxiety among Australian adults: findings from the National Survey of Mental Health and Well-Being. Soc Psychiatry Psychiatr Epidemiol 36 (2001) 219-227
16. Foote S.L., Bloom F.E., and Aston-Jones G. Nucleus locus coeruleus: new evidence of anatomical and physiological specificity. Physiol Rev 63 (1983) 844-914
17. Gonzalez S., Fernandez-Ruiz J., Di Marzo V., Hernandez M., Arevalo C., Nicanor C., et al. Behavioral and molecular changes elicited by acute administration of SR141716 to Delta9-tetrahydrocannabinol-tolerant rats: an experimental model of cannabinoid abstinence. Drug Alcohol Depend 74 (2004) 159-170
18. Grasing K., Bills D., Ghosh S., Schlussman S.D., Patel A.H., and Woodward J.J. Opiate modulation of striatal dopamine and hippocampal norepinephrine release following morphine withdrawal. Neurochem Res 22 (1997) 239-248
19. Gregg J.M., Small E.W., Moore R., Raft D., and Toomey T.C. Emotional response to intravenous delta9tetrahydrocannabinol during oral surgery. J Oral Surg 34 (1976) 301-313
20. Guitart X., Hayward M., Nisenbaum L.K., Beitner-Johnson D.B., Haycock J.W., and Nestler E.J. Identification of MARPP-58, a morphine- and cyclic AMP-regulated phosphoprotein of 58 kDa, as tyrosine hydroxylase: evidence for regulation of its expression by chronic morphine in the rat locus coeruleus. J Neurosci 10 (1990) 2649-2659
21. Hernandez M., Berrendero F., Suarez I., Garcia-Gil L., Cebeira M., Mackie K., et al. Cannabinoid CB(1) receptors colocalize with tyrosine hydroxylase in cultured fetal mesencephalic neurons and their activation increases the levels of this enzyme. Brain Res 857 (2000) 56-65
22. Jouvet M. Biogenic amines and the states of sleep. Science 163 (1969) 32-41
23. Kalant H. Adverse effects of cannabis on health: an update of the literature since 1996. Prog Neuropsychopharmacol Biol Psychiatry 28 (2004) 849-863
24. Kathuria S., Gaetani S., Fegley D., Valino F., Duranti A., Tontini A., et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9 (2003) 76-81
25. Koob G.F., Maldonado R., and Stinus L. Neural substrates of opiate withdrawal. Trends Neurosci 15 (1992) 186-191
26. Leonard B.E. Noradrenaline in basic models of depression. J Psychopharmacol 11 (1997) S39-S47
27. Lichtman A.H., and Martin B.R. Marijuana withdrawal syndrome in the animal model. J Clin Pharmacol 42 (2002) 20S-27S
28. Liu J., Merlie J.P., Todd R.D., and O'Malley K.L. Identification of cell type-specific promoter elements associated with the rat tyrosine hydroxylase gene using transgenic founder analysis. Brain Res Mol Brain Res 50 (1997) 33-42
29. Maldonado R. Study of cannabinoid dependence in animals. Pharmacol Ther 95 (2002) 153-164
30. Manzanares J., Uriguen L., Rubio G., and Palomo T. Role of endocannabinoid system in mental diseases. Neurotox Res 6 (2004) 213-224
31. Meyer R.E., Pillard R.C., Shapiro L.M., and Mirin S.M. Administration of marijuana to heavy and casual marijuana users. Am J Psychiatry 128 (1971) 198-204
32. Morgan J.I., and Curran T. Role of ion flux in the control of c-fos expression. Nature 322 (1986) 552-555
33. Morilak D.A., and Frazer A. Antidepressants and brain monoaminergic systems: a dimensional approach to understanding their behavioural effects in depression and anxiety disorders. Int J Neuropsychopharmacol 7 (2004) 193-218
34. Navarro M., Hernandez E., Munoz R.M., del Arco I., Villanua M.A., Carrera M.R., et al. Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. Neuroreport 8 (1997) 491-496
35. Oropeza V.C., Page M.E., Mackie K., and Van Bockstaele E.J. Cannabinoid receptor activation modulates frontal cortical norepinephrine efflux in rat brain. Program no. 690.1. 2004 abstract viewer/itinerary planner (2004), Society for Neuroscience, Washington, DC Online
36. Oropeza V.C., Page M.E., and Van Bockstaele E.J. Systemic administration of WIN 55,212-2 increases norepinephrine release in the rat frontal cortex. Brain Res 1046 (2005) 45-54
37. Oropeza V.C., Mackie K., and VanBockstaele E.J. Cannabinoid receptors are localized to noradrenergic axon terminals in the rat frontal cortex. Brain Res 1127 (2007) 36-44
38. Page M.E., and Lucki I. Effects of acute and chronic reboxetine treatment on stress-induced monoamine efflux in the rat frontal cortex. Neuropsychopharmacology 2 (2002) 237-247
39. Page M.E., Szeliga P., Gasparini F., and Cryan J.F. Blockade of the mGlu5 receptor decreases basal and stress-induced cortical norepinephrine in rodents. Psychopharmacology 179 (2005) 240-246
40. Paxinos G., and Watson C. The rat brain in stereotaxic coordinates. 2nd Edition (1986), Academic Press, San Diego
41. Persson M.L., Wasserman D., Geijer T., Jonsson E.G., and Terenius L. Tyrosine hydroxylase allelic distribution in suicide attempters. Psychiatry Res 72 (1997) 73-80
42. Rodriguez de Fonseca F., Rubio P., Menzaghi F., Merlo-Pich E., Rivier J., Koob G.F., et al. Corticotropin-releasing factor (CRF) antagonist [D-Phe12,Nle21,38,C alpha MeLeu37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats. J Pharmacol Exp Ther 276 (1996) 56-64
43. Sands S.A., Strong R., Corbitt J., and Morilak D.A. Effects of acute restraint stress on tyrosine hydroxylase mRNA expression in locus coeruleus of Wistar and Wistar-Kyoto rats. Brain Res Mol Brain Res 75 (2000) 1-7
44. Shishido T., Watanabe Y., Matsuoka I., Nakanishi H., and Niwa S. Acute methamphetamine administration increases tyrosine hydroxylase mRNA levels in the rat locus coeruleus. Brain Res Mol Brain Res 52 (1997) 146-150
45. Swanson D.J., Zellmer E., and Lewis E.J. AP1 proteins mediate the cAMP response of the dopamine beta-hydroxylase gene. J Biol Chem 273 (1998) 24065-24074
46. Troisi A., Pasini A., Saracco M., and Spalletta G. Psychiatric symptoms in male cannabis users not using other illicit drugs. Addiction 93 (1998) 487-492
47. Valentino R.J., Foote S.L., and Page M.E. The locus coeruleus as a site for integrating corticotropin-releasing factor and noradrenergic mediation of stress responses. Ann N Y Acad Sci 697 (1993) 173-188
48. Van Bockstaele E.J., Peoples J., and Valentino R.J. A.E. Bennett Research Award. Anatomic basis for differential regulation of the rostrolateral peri-locus coeruleus region by limbic afferents. Biol Psychiatry 46 (1999) 1352-1363
49. Weiss F., and Porrino L.J. Behavioral neurobiology of alcohol addiction: recent advances and challenges. J Neurosci 22 (2002) 3332-3337
50. Williams J.T., Christie M.J., and Manzoni O. Cellular and synaptic adaptations mediating opioid dependence. Physiol Rev 81 (2001) 299-343
51. Zuardi A.W., Shirakawa I., Finkelfarb E., and Karniol I.G. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology 76 (1982) 245-250